乳腺癌患者术后一年骨质疏松的相关因素分析

发布时间：2018-06-26 17:27

本文选题：乳腺癌 + 骨质疏松症　；参考：《中国骨质疏松杂志》2017年09期

【摘要】：目的探讨乳腺癌患者术后1年合并骨质疏松症的相关因素。方法选取41例乳腺癌术后1年合并骨质疏松症患者为骨质疏松组(OP组),年龄53~75岁;56例骨密度正常的乳腺癌患者为非骨质疏松组(NOP组),年龄46~64岁。采用美国GE公司产的双能X线骨密度仪测定入组患者左侧股骨颈、腰椎1-4(L1-4)骨密度,并分析其与年龄、体重指数(BMI)、生产、绝经、绝经年限、雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(HER-2)等的相关性。结果 OP组年龄、体重指数(BMI)、绝经及绝经年限与NOP组比较,差异有统计学意义(P0.05),而两组雌激素受体(ER)、孕激素受体(PR)、人表皮生长因子受体2(HER-2)阳性及是否生产之间比较无明显差异(P0.05)。相关性分析显示腰椎BMD与BMI呈正相关,而与年龄、绝经年限呈负相关。结论乳腺癌妇女骨质疏松症患病率较高,年龄、绝经年限、BMI为影响骨质疏松的关键因素。
[Abstract]:Objective to investigate the factors associated with osteoporosis in 1 years after operation of breast cancer. Methods 41 cases of osteoporosis in 1 years after operation of breast cancer were selected as osteoporosis group (group OP), age 53~75 years, and 56 cases of normal bone density of breast cancer patients were non osteoporosis group (group NOP), age 46~64 years. The dual energy X ray produced by American GE company was used. The bone densitometer measured the left femoral neck and lumbar 1-4 (L1-4) bone density in the patients and analyzed their correlation with age, body mass index (BMI), production, menopause, menopause, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2). Results the age of OP group, body mass index (BMI), menopause and menopause and NOP ratio The difference was statistically significant (P0.05), but there was no significant difference between the two groups of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2) and production (P0.05). The correlation analysis showed that the lumbar BMD was positively correlated with BMI, but was negatively correlated with age and menopause. Prevalence is high, age, menopausal age, and BMI are the key factors affecting osteoporosis.
【作者单位】：广东省中医院芳村分院影像科;广东省中医院大德路总院影像科;
【分类号】：R580;R737.9

【相似文献】